Dyspareunia Treatment Market

Dyspareunia Treatment Market (Treatment Type: Drug and Drug-device Combination; Route of Administration: Oral and Vaginal Inserts) - Global Industry Analysis, Size, Share, Growth, Trends, and Forecast, 2022-2031

Dyspareunia Treatment Market Outlook 2031

  • The global market was valued at US$ 689.0 Mn in 2021
  • The global market is projected to grow at a CAGR of 4.1% from 2022 to 2031
  • The global dyspareunia treatment industry is anticipated to reach more than US$ 1.02 Bn by the end of 2031

Analysts’ Viewpoint on Global Market Scenario

Genital pain during or after sexual activity is known as dyspareunia or coitalgia. Painful sex can be experienced internally in the vagina, uterus, or pelvis as well as outwardly on the vulva. Sexual activity can be uncomfortable due to infections or underlying medical issues. Usually, the underlying source of discomfort is found and treated. Rise in number of women with painful coitus is expected to propel the global market during the forecast period. Dyspareunia treatment market trends include rise in prevalence of dyspareunia, which is augmenting the research and development in painful intercourse treatment or painful coitus treatment. Leading players in the market are investing and collaborating on novel drug options for dyspareunia treatment or coitalgia treatment.

Dyspareunia Treatment Market

Dyspareunia Treatment Market Introduction

A new non-estrogen topical medication called prasterone (Intrarosa) is available in the market and is licensed for the treatment of moderate-to-severe dyspareunia caused due to menopause. There have not been any direct comparison studies between prasterone and vaginal estrogen. In one trial, prasterone outperformed placebo and increased the female sexual function index scores after just 12 weeks of treatment. Prasterone is thought to function by locally converting androstenedione and testosterone to estrone and estradiol in the vagina. Most doctors consider this to be the second-line treatment for patients who do not wish to use estrogen due to its daily dosage and lack of proven superiority to estrogen. Additionally, less insurance coverage could be available for newer brand-name drugs such as Intrarosa and Imvexxy than for more seasoned estrogen supplements, restricting their availability.

The oral medication ospemifene is intended only for the treatment of moderate-to-severe dyspareunia brought on by GSM. Ospemifene, an estrogen agonist that was approved in 2013, functions as a selective estrogen receptor modulator in the vagina but does not seem to activate breast and endometrial cells. Typically, women who prefer not to use vaginal products or who are unable to do so are given this daily oral option. Ospemifene and vaginal estrogen have not been compared in head-to-head studies, unlike prasterone.

Request a sample to get extensive insights into the Dyspareunia Treatment Market

Inclination toward Non-invasive Treatment Options to Propel Global Dyspareunia Treatment Market

People prefer painless and instant recovery solutions over their injury or physical issues. Therefore, the demand for non-invasive treatment is increasing rapidly across the globe. The non-invasive treatment is one of the most sophisticated options for dyspareunia, as it is related to genital organs and people are not ready to take the risk. Hence, they prefer non-invasive treatments. This kind of treatment has minimal to no pain or discomfort, with no incisions, stitches, or any kind of scars. Long hospital stay is not required in this treatment unlike other surgeries. Non-invasive treatments carry very less risk of complications and are available at an affordable price. For instance, in May 2021, Pfizer and Myovant Sciences’ Myfembree (relugolix, estradiol, and norethindrone acetate) became the first once-daily U.S. Food and Drug Administration (FDA) approved treatment for heavy menstrual bleeding associated with uterine fibroids in premenopausal women, with treatment duration of up to 24 months. This milestone marked a critical step forward in a disease area that has previously had limited non-invasive treatment options and significant reliance on surgical procedures such as hysterectomies.

Urinary Tract Symptoms and Emotional Issues or Stress Fueling Global Dyspareunia Treatment Market Size

Dyspareunia is one of the most prevalent issues affecting postmenopausal women. According to the American College of Obstetricians and Gynecologists, more than 75% of women experience painful sex at some point (ACOG). Younger age, education below a college degree, urinary tract symptoms, poor to fair health, emotional issues or stress, and a decrease in household income of more than 20% are significant risk factors and predictors for dyspareunia. These can also result in sexual issues such as a lack of arousal and desire, which can be problematic in intimate relationships. Both emotional and physical health could be significantly affected by it. Dyspareunia can cause low self-esteem, negative body image, anxiety, and hypervigilance to pain. Recurrent or chronic genital or pelvic pain accompanied by sexual activity or sexual dysfunction that lasts for three months or more is known as male dyspareunia. The illness often causes humiliation and could be challenging for the patient and the doctor to discuss openly.

Request a custom report on Dyspareunia Treatment Market

Approval of New Drugs to Bolster Drug Segment

In terms of treatment type, the global market has been bifurcated into drug and drug-device combinations. The drug segment has been split into estrogens, miscellaneous vaginal agents, selective estrogen receptor modulators, and others. The drug segment accounted for the largest global dyspareunia treatment market share in 2021 due to recent drug approvals by the U.S. FDA. For instance, on August 5, 2022, the U.S. FDA approved Myovant Sciences and Pfizer's once-daily medication MYFEMBREE for the treatment of moderate to severe pain brought on by endometriosis. MYFEMBREE is currently available and will continue to be commercialized jointly by Myovant and Pfizer.

Patient Compliance Toward Oral Route of Administration to Propel Oral Segment

Based on the route of administration, the global dyspareunia treatment market has been segregated into oral and vaginal inserts. Oral is the most common route of drug administration. It is the most preferred route due to advantages such as non-invasiveness, patient compliance, and convenience of drug administration.

Regional Outlook of Global Dyspareunia Treatment Industry

As per the dyspareunia treatment market analysis, North America accounted for a significant share of the global dyspareunia treatment in 2021. According to the World Health Organization (WHO), the prevalence of dyspareunia in the U.S. stands at around 10% to 20%, with the leading causes varying by age group. Painful sex or dyspareunia is reported among 7.5% of women in the U.K. The disease is linked to poorer sexual, physical, relational, and mental health. Asia Pacific is likely to be the fastest-growing region for dyspareunia treatment due to the increase in awareness about dyspareunia treatment among women in the region.

Analysis of Key Players in the Global Dyspareunia Treatment Business

The report concludes with the company profiles section, which includes information about key players in the global dyspareunia treatment market. Expansion of product portfolio and mergers & acquisitions are the key strategies adopted by the leading players in the market. Duchesnay, Inc., AMAG Pharmaceuticals, Inc., Amneal Pharmaceuticals, TherapeuticsMd, Inc., Myovant Sciences, Novo Nordisk, Inc., Pfizer, and Viatris Inc. are the prominent players in the global dyspareunia treatment business.

Key Developments in Global Dyspareunia Treatment Market

  • On February 14, 2022, Duchesnay, Inc., a pharmaceutical company specializing in women's health and part of the Duchesnay Pharmaceutical Group based in Blainville, Quebec, announced the first treatment launched to help postmenopausal women suffering from vaginal dryness and painful intercourse across Canada. Osphena (ospemifene tablets), a Selective Estrogen Receptor Modulator (SERM) now available across Canada, has been approved by Health Canada as a once-daily prescription treatment for this indication.
  • On September 13, 2018, TherapeuticsMD, Inc., an innovative women’s healthcare company, announced the commercial availability of Imvexxy (estradiol vaginal inserts) 4 mcg dose in the U.S. Imvexxy 4 mcg is the lowest-dose vaginal estrogen product approved by the U.S. Food and Drug Administration (FDA) for the treatment of moderate-to-severe dyspareunia (vaginal pain associated with sexual activity), a symptom of vulvar and vaginal atrophy (VVA), due to menopause.

Each of these players has been profiled in the dyspareunia treatment market report based on parameters such as company overview, financial overview, business strategies, product portfolio, business segments, and recent developments.

Global Dyspareunia Treatment Market Snapshot

Attribute

Detail

Market Size Value in 2021

US$ 689.0 Mn

Market Forecast Value in 2031

More than US$ 1.02 Bn

Growth Rate (CAGR) for 2022-2031

4.1%

Forecast Period

2022–2031

Historical Data Available for

2017–2020

Quantitative Units

US$ Mn/Bn for Value

Market Analysis

It includes segment analysis as well as regional level analysis. Moreover, the qualitative analysis includes market drivers, restraints, opportunities, key trends, and a parent industry overview.

Competition Landscape

  • Market share analysis by the company (2021)
  • Company profiles section includes an overview, product portfolio, sales footprint, key subsidiaries or distributors, strategy & recent developments, and key financials

Format

Electronic (PDF) + Excel

Market Segmentation

  • Treatment Type
    • Drug
      • Estrogens, Miscellaneous Vaginal Agents
      • Selective Estrogen Receptor Modulators
      • Others
    • Drug-device Combination
  • Route of Administration
    • Oral
    • Vaginal Inserts
  • Distribution Channel
    • Retail Pharmacies
    • E-commerce
    • Others

Regions Covered

  • North America
  • Latin America
  • Europe
  • Latin America
  • Middle East & Africa

Countries Covered

  • U.S.
  • Canada
  • Germany
  • U.K.
  • France
  • Italy
  • Spain
  • Japan
  • China
  • India
  • Australia & New Zealand
  • Brazil
  • Mexico
  • Rest of Latin America
  • GCC Countries
  • South Africa

Companies Profiled

  • Duchesnay, Inc.
  • AMAG Pharmaceuticals, Inc.
  • Amneal Pharmaceuticals
  • TherapeuticsMD, Inc.
  • Myovant Sciences
  • Novo Nordisk, Inc.
  • Pfizer
  • Viatris, Inc.

Customization Scope

Available upon request

Pricing

Available upon request

Frequently Asked Questions

How big was the global dyspareunia treatment market in 2021?

The global market for dyspareunia treatment was valued at US$ 689.0 Mn in 2021.

How big will be the global dyspareunia treatment industry in 2031?

The global market is projected to reach more than US$ 1.02 Bn by 2031.

What was the CAGR of the global market for dyspareunia treatment from 2017 to 2021?

The global market grew at a CAGR of 9.3% from 2017 to 2021.

What will be the CAGR of the global dyspareunia treatment market during the forecast period (2022–2031)?

The global market for dyspareunia treatment is anticipated to grow at a CAGR of 4.1% from 2022 to 2031.

What is the market share of the leading segment of the global dyspareunia treatment?

The drug segment held more than 63% share of the global market in 2021.

Which region will account for the major share of the global market during the forecast period?

North America is expected to account for the major share of the global market during the forecast period.

Who are the prominent players in the global dyspareunia treatment business?

Duchesnay, Inc., AMAG Pharmaceuticals, Inc., Amneal Pharmaceuticals, TherapeuticsMD, Inc., Myovant Sciences, Novo Nordisk, Inc., Pfizer, and Viatris, Inc.

    1. Preface

        1.1. Market Definition and Scope

        1.2. Market Segmentation

        1.3. Key Research Objectives

        1.4. Research Highlights

    2. Assumptions and Research Methodology

    3. Executive Summary: Global Dyspareunia Treatment Market

    4. Market Overview

        4.1. Introduction

            4.1.1. Treatment Type Definition

            4.1.2. Industry Evolution / Developments

        4.2. Overview

        4.3. Market Dynamics

            4.3.1. Drivers

            4.3.2. Restraints

            4.3.3. Opportunities

        4.4. Global Dyspareunia Treatment Market Analysis and Forecast, 2017–2031

            4.4.1. Market Revenue Projections (US$ Mn)

    5. Key Insights

        5.1. Pipeline Analysis

        5.2. Disease Prevalence & Incidence Rate globally with key countries

        5.3. Key Industry Events (mergers, acquisitions, partnerships, etc.)

        5.4. COVID-19 Pandemic Impact on Industry (value chain and short / mid / long term impact)

    6. Global Dyspareunia Treatment Market Analysis and Forecast, by Treatment Type

        6.1. Introduction & Definition

        6.2. Key Findings / Developments

        6.3. Market Value Forecast, by Treatment Type, 2017–2031

            6.3.1. Drug

                6.3.1.1. Estrogens, Miscellaneous Vaginal Agents

                6.3.1.2. Selective Estrogen Receptor Modulators

                6.3.1.3. Others

            6.3.2. Drug-device Combination

        6.4. Market Attractiveness Analysis, by Treatment Type

    7. Global Dyspareunia Treatment Market Analysis and Forecast, by Route of Administration

        7.1. Introduction & Definition

        7.2. Key Findings / Developments

        7.3. Market Value Forecast, by Route of Administration, 2017–2031

            7.3.1. Oral

            7.3.2. Vaginal Inserts

        7.4. Market Attractiveness Analysis, by Route of Administration

    8. Global Dyspareunia Treatment Market Analysis and Forecast, by Distribution Channel

        8.1. Introduction & Definition

        8.2. Key Findings / Developments

        8.3. Market Value Forecast, by Distribution Channel, 2017–2031

            8.3.1. Retail Pharmacies

            8.3.2. E-commerce

            8.3.3. Others

        8.4. Market Attractiveness Analysis, by Distribution Channel

    9. Global Dyspareunia Treatment Market Analysis and Forecast, by Region

        9.1. Key Findings

        9.2. Market Value Forecast, by Region

            9.2.1. North America

            9.2.2. Europe

            9.2.3. Asia Pacific

            9.2.4. Latin America

            9.2.5. Middle East & Africa

        9.3. Market Attractiveness Analysis, by Region

    10. North America Dyspareunia Treatment Market Analysis and Forecast

        10.1. Introduction

            10.1.1. Key Findings

        10.2. Market Value Forecast, by Treatment Type, 2017–2031

            10.2.1. Drug

                10.2.1.1. Estrogens, Miscellaneous Vaginal Agents

                10.2.1.2. Selective Estrogen Receptor Modulators

                10.2.1.3. Others

            10.2.2. Drug-device Combination

        10.3. Market Value Forecast, by Route of Administration, 2017–2031

            10.3.1. Oral

            10.3.2. Vaginal Inserts

        10.4. Market Value Forecast, by Distribution Channel, 2017–2031

            10.4.1. Retail Pharmacies

            10.4.2. E-commerce

            10.4.3. Others

        10.5. Market Value Forecast, by Country, 2017–2031

            10.5.1. U.S.

            10.5.2. Canada

        10.6. Market Attractiveness Analysis

            10.6.1. By Treatment Type

            10.6.2. By Route of Administration

            10.6.3. By Distribution Channel

            10.6.4. By Country

    11. Europe Dyspareunia Treatment Market Analysis and Forecast

        11.1. Introduction

            11.1.1. Key Findings

        11.2. Market Value Forecast, by Treatment Type, 2017–2031

            11.2.1. Drug

                11.2.1.1. Estrogens, Miscellaneous Vaginal Agents

                11.2.1.2. Selective Estrogen Receptor Modulators

                11.2.1.3. Others

            11.2.2. Drug-device Combination

        11.3. Market Value Forecast, by Route of Administration, 2017–2031

            11.3.1. Oral

            11.3.2. Vaginal Inserts

        11.4. Market Value Forecast, by Distribution Channel, 2017–2031

            11.4.1. Retail Pharmacies

            11.4.2. E-commerce

            11.4.3. Others

        11.5. Market Value Forecast, by Country/Sub-region, 2017–2031

            11.5.1. Germany

            11.5.2. UK

            11.5.3. France

            11.5.4. Italy

            11.5.5. Spain

            11.5.6. Rest of Europe

        11.6. Market Attractiveness Analysis

            11.6.1. By Treatment Type

            11.6.2. By Route of Administration

            11.6.3. By Distribution Channel

            11.6.4. By Country/Sub-region

    12. Asia Pacific Dyspareunia Treatment Market Analysis and Forecast

        12.1. Introduction

            12.1.1. Key Findings

        12.2. Market Value Forecast, by Treatment Type, 2017–2031

            12.2.1. Drug

                12.2.1.1. Estrogens, Miscellaneous Vaginal Agents

                12.2.1.2. Selective Estrogen Receptor Modulators

                12.2.1.3. Others

            12.2.2. Drug-device Combination

        12.3. Market Value Forecast, by Route of Administration, 2017–2031

            12.3.1. Oral

            12.3.2. Vaginal Inserts

        12.4. Market Value Forecast, by Distribution Channel, 2017–2031

            12.4.1. Retail Pharmacies

            12.4.2. E-commerce

            12.4.3. Others

        12.5. Market Value Forecast, by Country/Sub-region, 2017–2031

            12.5.1. China

            12.5.2. India

            12.5.3. Japan

            12.5.4. Australia & New Zealand

            12.5.5. Rest of Asia Pacific

        12.6. Market Attractiveness Analysis

            12.6.1. By Treatment Type

            12.6.2. By Route of Administration

            12.6.3. By Distribution Channel

            12.6.4. By Country/Sub-region

    13. Latin America Dyspareunia Treatment Market Analysis and Forecast

        13.1. Introduction

            13.1.1. Key Findings

        13.2. Market Value Forecast, by Treatment Type, 2017–2031

            13.2.1. Drug

                13.2.1.1. Estrogens, Miscellaneous Vaginal Agents

                13.2.1.2. Selective Estrogen Receptor Modulators

                13.2.1.3. Others

            13.2.2. Drug-device Combination

        13.3. Market Value Forecast, by Route of Administration, 2017–2031

            13.3.1. Oral

            13.3.2. Vaginal Inserts

        13.4. Market Value Forecast, by Distribution Channel, 2017–2031

            13.4.1. Retail Pharmacies

            13.4.2. E-commerce

            13.4.3. Others

        13.5. Market Value Forecast, by Country/Sub-region, 2017–2031

            13.5.1. Brazil

            13.5.2. Mexico

            13.5.3. Rest of Latin America

        13.6. Market Attractiveness Analysis

            13.6.1. By Treatment Type

            13.6.2. By Route of Administration

            13.6.3. By Distribution Channel

            13.6.4. By Country/Sub-region

    14. Middle East & Africa Dyspareunia Treatment Market Analysis and Forecast

        14.1. Introduction

            14.1.1. Key Findings

        14.2. Market Value Forecast, by Treatment Type, 2017–2031

            14.2.1. Drug

                14.2.1.1. Estrogens, Miscellaneous Vaginal Agents

                14.2.1.2. Selective Estrogen Receptor Modulators

                14.2.1.3. Others

            14.2.2. Drug-device Combination

        14.3. Market Value Forecast, by Route of Administration, 2017–2031

            14.3.1. Oral

            14.3.2. Vaginal Inserts

        14.4. Market Value Forecast, by Distribution Channel, 2017–2031

            14.4.1. Retail Pharmacies

            14.4.2. E-commerce

            14.4.3. Others

        14.5. Market Value Forecast, by Country/Sub-region, 2017–2031

            14.5.1. GCC

            14.5.2. South Africa

            14.5.3. Rest of Middle East & Africa

        14.6. Market Attractiveness Analysis

            14.6.1. By Treatment Type

            14.6.2. By Route of Administration

            14.6.3. By Distribution Channel

            14.6.4. By Country/Sub-region

    15. Competition Landscape

        15.1. Market Player – Competition Matrix (By Tier and Size of companies)

        15.2. Market Share Analysis By Company (2021)

        15.3. Company Profiles

            15.3.1. Duchesnay, Inc.

                15.3.1.1. Company Overview (HQ, Business Segments, Employee Strength)

                15.3.1.2. Company Financials

                15.3.1.3. Growth Strategies

                15.3.1.4. SWOT Analysis

            15.3.2. AMAG Pharmaceuticals, Inc.

                15.3.2.1. Company Overview (HQ, Business Segments, Employee Strength)

                15.3.2.2. Company Financials

                15.3.2.3. Growth Strategies

                15.3.2.4. SWOT Analysis

            15.3.3. Amneal Pharmaceuticals

                15.3.3.1. Company Overview (HQ, Business Segments, Employee Strength)

                15.3.3.2. Company Financials

                15.3.3.3. Growth Strategies

                15.3.3.4. SWOT Analysis

            15.3.4. TherapeuticsMD, Inc.

                15.3.4.1. Company Overview (HQ, Business Segments, Employee Strength)

                15.3.4.2. Company Financials

                15.3.4.3. Growth Strategies

                15.3.4.4. SWOT Analysis

            15.3.5. Myovant Sciences

                15.3.5.1. Company Overview (HQ, Business Segments, Employee Strength)

                15.3.5.2. Company Financials

                15.3.5.3. Growth Strategies

                15.3.5.4. SWOT Analysis

            15.3.6. Novo Nordisk, Inc.

                15.3.6.1. Company Overview (HQ, Business Segments, Employee Strength)

                15.3.6.2. Company Financials

                15.3.6.3. Growth Strategies

                15.3.6.4. SWOT Analysis

            15.3.7. Pfizer

                15.3.7.1. Company Overview (HQ, Business Segments, Employee Strength)

                15.3.7.2. Company Financials

                15.3.7.3. Growth Strategies

                15.3.7.4. SWOT Analysis

            15.3.8. Viatris, Inc.

                15.3.8.1. Company Overview (HQ, Business Segments, Employee Strength)

                15.3.8.2. Company Financials

                15.3.8.3. Growth Strategies

                15.3.8.4. SWOT Analysis

    List of Tables

    Table 01: Global Dyspareunia Market Value (US$ Mn) Forecast, by Treatment Type, 2017–2031

    Table 02: Global Dyspareunia Market Value (US$ Mn) Forecast, by Route of Administration, 2017–2031

    Table 03: Global Dyspareunia Market Value (US$ Mn) Forecast, by Distribution Channel, 2017–2031

    Table 04: Global Dyspareunia Market Value (US$ Mn) Forecast, by Region, 2017–2031

    Table 05: North America Dyspareunia Market Value (US$ Mn) Forecast, by Treatment Type, 2017–2031

    Table 06: North America Dyspareunia Market Value (US$ Mn) Forecast, by Route of Administration, 2017–2031

    Table 07: North America Dyspareunia Market Value (US$ Mn) Forecast, by Distribution Channel, 2017–2031

    Table 08: North America Dyspareunia Market Value (US$ Mn) Forecast, by Country, 2017–2031

    Table 09: Europe Dyspareunia Market Value (US$ Mn) Forecast, by Treatment Type, 2017–2031

    Table 10: Europe Dyspareunia Market Value (US$ Mn) Forecast, by Route of Administration, 2017–2031

    Table 11: Europe Dyspareunia Market Value (US$ Mn) Forecast, by Distribution Channel, 2017–2031

    Table 12: Europe Dyspareunia Market Value (US$ Mn) Forecast, by Country/Sub-region, 2017–2031

    Table 13: Asia Pacific Dyspareunia Market Value (US$ Mn) Forecast, by Treatment Type, 2017–2031

    Table 14: Asia Pacific Dyspareunia Market Value (US$ Mn) Forecast, by Route of Administration, 2017–2031

    Table 15: Asia Pacific Dyspareunia Market Value (US$ Mn) Forecast, by Distribution Channel, 2017–2031

    Table 16: Asia Pacific Dyspareunia Market Value (US$ Mn) Forecast, by Country/Sub-region, 2017–2031

    Table 17: Latin America Dyspareunia Market Value (US$ Mn) Forecast, by Treatment Type, 2017–2031

    Table 18: Latin America Dyspareunia Market Value (US$ Mn) Forecast, by Route of Administration, 2017–2031

    Table 19: Latin America Dyspareunia Market Value (US$ Mn) Forecast, by Distribution Channel, 2017–2031

    Table 20: Latin America Dyspareunia Market Value (US$ Mn) Forecast, by Country/Sub-region, 2017–2031

    Table 21: Middle East & Africa Dyspareunia Market Value (US$ Mn) Forecast, by Treatment Type, 2017–2031

    Table 22: Middle East & Africa Dyspareunia Market Value (US$ Mn) Forecast, by Route of Administration, 2017–2031

    Table 23: Middle East & Africa Dyspareunia Market Value (US$ Mn) Forecast, by Distribution Channel, 2017–2031

    Table 24: Middle East & Africa Dyspareunia Market Value (US$ Mn) Forecast, by Country/Sub-region, 2017–2031

    List of Figures

    Figure 01: Global Dyspareunia Market Value (US$ Mn) Forecast and Y-o-Y Growth (%) Projection, 2017–2031

    Figure 02: Global Dyspareunia Market Value Share Analysis, by Treatment Type, 2021 and 2031

    Figure 03: Global Dyspareunia Market Attractiveness Index Analysis, by Treatment Type, 2022–2031

    Figure 04: Global Dyspareunia Market Revenue (US$ Mn), by Drug Market, 2017–2031

    Figure 05: Global Dyspareunia Market Revenue (US$ Mn), by Drug-device Combination Market, 2017–2031

    Figure 06: Global Dyspareunia Market Value Share Analysis, by Route of Administration, 2021 and 2031

    Figure 07: Global Dyspareunia Market Attractiveness Index Analysis, by Route of Administration, 2022–2031

    Figure 08: Global Dyspareunia Market Revenue (US$ Mn), by Oral, 2017–2031

    Figure 09: Global Dyspareunia Market Revenue (US$ Mn), by Vaginal Inserts, 2017–2031

    Figure 10: Global Dyspareunia Market Value Share Analysis, by Distribution Channel, 2021 and 2031

    Figure 11: Global Dyspareunia Market Attractiveness Index Analysis, by Distribution Channel, 2022–2031

    Figure 12: Global Dyspareunia Market Revenue (US$ Mn), by Retail Pharmacies, 2017–2031

    Figure 13: Global Dyspareunia Market Revenue (US$ Mn), by E-commerce, 2017–2031

    Figure 14: Global Dyspareunia Market Revenue (US$ Mn), by Others, 2017–2031

    Figure 15: Global Dyspareunia Market Value Share Analysis, by Region, 2021 and 2031

    Figure 16: Global Dyspareunia Market Attractiveness Analysis, by Region, 2021–2031

    Figure 17: North America Dyspareunia Market Value (US$ Mn) Forecast and Y-o-Y Growth (%) Projection, 2017–2031

    Figure 18: North America Dyspareunia Market Value Share Analysis, by Treatment Type, 2021 and 2031

    Figure 19: North America Dyspareunia Market Attractiveness Index Analysis, by Treatment Type, 2022–2031

    Figure 20: North America Dyspareunia Market Value Share Analysis, by Route of Administration, 2021 and 2031

    Figure 21: North America Dyspareunia Market Attractiveness Index Analysis, by Route of Administration, 2022–2031

    Figure 22: North America Dyspareunia Market Value Share Analysis, by Distribution Channel, 2021 and 2031

    Figure 23: North America Dyspareunia Market Attractiveness Index Analysis, by Distribution Channel, 2022–2031

    Figure 24: North America Dyspareunia Market Value Share Analysis, by Country, 2021 and 2031

    Figure 25: North America Dyspareunia Market Attractiveness Analysis, by Country, 2022–2031

    Figure 26: Europe Dyspareunia Market Value (US$ Mn) Forecast and Y-o-Y Growth (%) Projection, 2017–2031

    Figure 27: Europe Dyspareunia Market Value Share Analysis, by Treatment Type, 2021 and 2031

    Figure 28: Europe Dyspareunia Market Attractiveness Index Analysis, by Treatment Type, 2022–2031

    Figure 29: Europe Dyspareunia Market Value Share Analysis, by Route of Administration, 2021 and 2031

    Figure 30: Europe Dyspareunia Market Attractiveness Index Analysis, by Route of Administration, 2022–2031

    Figure 31: Europe Dyspareunia Market Value Share Analysis, by Distribution Channel, 2021 and 2031

    Figure 32: Europe Dyspareunia Market Attractiveness Index Analysis, by Distribution Channel, 2022–2031

    Figure 33: Europe Dyspareunia Market Value Share Analysis, by Country/Sub-region, 2021 and 2031

    Figure 34: Europe Dyspareunia Market Attractiveness Analysis, by Country/Sub-region, 2022–2031

    Figure 35: Asia Pacific Dyspareunia Market Value (US$ Mn) Forecast and Y-o-Y Growth (%) Projection, 2017–2031

    Figure 36: Asia Pacific Dyspareunia Market Value Share Analysis, by Treatment Type, 2021 and 2031

    Figure 37: Asia Pacific Dyspareunia Market Attractiveness Index Analysis, by Treatment Type, 2022–2031

    Figure 38: Asia Pacific Dyspareunia Market Value Share Analysis, by Route of Administration, 2021 and 2031

    Figure 39: Asia Pacific Dyspareunia Market Attractiveness Index Analysis, by Route of Administration, 2022–2031

    Figure 40: Asia Pacific Dyspareunia Market Value Share Analysis, by Distribution Channel, 2021 and 2031

    Figure 41: Asia Pacific Dyspareunia Market Attractiveness Index Analysis, by Distribution Channel, 2022–2031

    Figure 42: Asia Pacific Dyspareunia Market Value Share Analysis, by Country/Sub-region, 2021 and 2031

    Figure 43: Asia Pacific Dyspareunia Market Attractiveness Analysis, by Country/Sub-region, 2022–2031

    Figure 44: Latin America Dyspareunia Market Value (US$ Mn) Forecast and Y-o-Y Growth (%) Projection, 2017–2031

    Figure 45: Latin America Dyspareunia Market Value Share Analysis, by Treatment Type, 2021 and 2031

    Figure 46: Latin America Dyspareunia Market Attractiveness Index Analysis, by Treatment Type, 2022–2031

    Figure 47: Latin America Dyspareunia Market Value Share Analysis, by Route of Administration, 2021 and 2031

    Figure 48: Latin America Dyspareunia Market Attractiveness Index Analysis, by Route of Administration, 2022–2031

    Figure 49: Latin America Dyspareunia Market Value Share Analysis, by Distribution Channel, 2021 and 2031

    Figure 50: Latin America Dyspareunia Market Attractiveness Index Analysis, by Distribution Channel, 2022–2031

    Figure 51: Latin America Dyspareunia Market Value Share Analysis, by Country/Sub-region, 2021 and 2031

    Figure 52: Latin America Dyspareunia Market Attractiveness Analysis, by Country/Sub-region, 2022–2031

    Figure 53: Middle East & Africa Dyspareunia Market Value (US$ Mn) Forecast and Y-o-Y Growth (%) Projection, 2017–2031

    Figure 54: Middle East & Africa Dyspareunia Market Value Share Analysis, by Treatment Type, 2021 and 2031

    Figure 55: Middle East & Africa Dyspareunia Market Attractiveness Index Analysis, by Treatment Type, 2022–2031

    Figure 56: Middle East & Africa Dyspareunia Market Value Share Analysis, by Route of Administration, 2021 and 2031

    Figure 57: Middle East & Africa Dyspareunia Market Attractiveness Index Analysis, by Route of Administration, 2022–2031

    Figure 58: Middle East & Africa Dyspareunia Market Value Share Analysis, by Distribution Channel, 2021 and 2031

    Figure 59: Middle East & Africa Dyspareunia Market Attractiveness Index Analysis, by Distribution Channel, 2022–2031

    Figure 60: Middle East & Africa Dyspareunia Market Value Share Analysis, by Country/Sub-region, 2021 and 2031

    Figure 61: Middle East & Africa Dyspareunia Market Attractiveness Index Analysis, by Country/Sub-region, 2022–2031

Copyright © Transparency Market Research, Inc. All Rights reserved